Comparative Pharmacology
Head-to-head clinical analysis: ENULOSE versus TURGEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENULOSE versus TURGEX.
ENULOSE vs TURGEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic pH and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
TURGEX is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin into presynaptic neurons.
15-45 mL orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 mL per day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Terminal half-life 8.2 ± 1.5 hours; extends to 15–20 hours in moderate hepatic impairment (Child-Pugh B) and to 12–14 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Approximately 70% renal (60% unchanged, 10% as inactive glucuronide conjugate), 20% fecal via biliary elimination, and 10% metabolized by hepatic CYP3A4 to minor metabolites
Category C
Category C
Laxative
Laxative